What is Tedor Pharma?
Tedor Pharma operates as a US-based contract development and manufacturing organization (CDMO) with a specialized focus on the production of high-quality solid dose pharmaceuticals and controlled substances. Leveraging over two decades of industry experience, the company provides a comprehensive suite of services, encompassing formulation and process development, analytical services, clinical trial supply, and commercial manufacturing of solid dose products. Their advanced facility is both FDA registered and DEA licensed, ensuring adherence to stringent quality and regulatory standards throughout the drug development lifecycle. Tedor Pharma positions itself as a strategic partner, offering flexible, end-to-end outsourcing solutions designed to meet the specific requirements of small molecule drug products.
How much funding has Tedor Pharma raised?
Tedor Pharma has raised a total of $1.9M across 2 funding rounds:
Debt
$1M
Debt
$949K
Debt (2020): $1M with participation from PPP
Debt (2021): $949K led by PPP
What's next for Tedor Pharma?
The substantial enterprise-level capital infusion signifies a pivotal moment for Tedor Pharma, likely enabling significant expansion of its manufacturing capabilities, investment in advanced technologies, and potentially broadening its service offerings. This strategic backing is expected to accelerate the company's growth trajectory, allowing it to capture a larger share of the burgeoning CDMO market. Future developments may include increased capacity for complex formulations, enhanced R&D support for clients, and further integration of its supply chain services to provide a more seamless drug development pathway. The company's focus on controlled substances and solid dose manufacturing positions it to capitalize on growing demand in these specialized pharmaceutical segments.
See full Tedor Pharma company page
